Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
about
Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1ErbB2 signaling at the crossing between heart failure and cancerCLO: The cell line ontologyUse of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.Cardiotoxicity associated with targeted cancer therapies.Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.Effects of a human compact anti-ErbB2 antibody on gastric cancer.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
P2860
Q26771931-406F6D18-D928-4D99-9599-75761B48FC24Q28075244-46CF571F-671F-453A-AA2D-B4258ACDDD23Q28650204-EEA7ED7A-6129-43C7-98FF-D789D93292D0Q30402943-FE027EAF-D849-435D-AE84-8069C4B318DDQ36153375-65EC0D23-5661-4E37-A800-53C31271C47DQ37131070-D5E846CD-6BBF-476E-8867-02799D7E35E7Q37397983-678C1266-D3F5-4010-9EEA-7E78F62F1F81Q37586081-2379DF0D-E467-44E0-B2F7-7ADB263D252BQ38207484-D92FCABC-1494-49B6-93A4-9059EC4FC33BQ38774086-FCAFB9A3-A2D9-4D3A-8847-2AD9A84D22EAQ38819670-A60C94F1-7DC5-4327-A2D3-340CAB29FA8FQ38877306-D3A787C3-FA6A-49FA-988E-BDEB48270467Q39185414-F68C779F-E14E-472B-9751-31BA889814D7Q39344380-D6E8C8AC-DD5F-4485-8C6D-B6E42A056624Q46269647-609CB419-8295-4D33-B4C5-EA13703567D3Q49315568-F577C4CA-BCCF-4F52-B1B9-08AF62C29983
P2860
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
@en
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
@nl
type
label
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
@en
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
@nl
prefLabel
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
@en
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
@nl
P2093
P2860
P1476
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors
@en
P2093
Angela Eliana Malara
Carmine Fedele
Giuseppe D'Alessio
P2860
P2888
P304
P356
10.1007/S10549-012-2103-8
P407
P577
2012-06-07T00:00:00Z